Neurol. praxi. 2014;15(2):105-108

Léčba Parkinsonovy nemoci

  
  

  

Keywords:   

Published: May 10, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Léčba Parkinsonovy nemoci. Neurol. praxi. 2014;15(2):105-108.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bareš M, Rektorová I, Jech R, Farníková K, Roth J, Růžička E, Kaňovský P, Rektor I, Pavlík T, Uhlířová L, Vydlák J. Does WOQ9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease? J Neural Transm 2012; 119(3): 373-380. Go to original source... Go to PubMed...
    2. Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24(7): 993-1000. Go to original source... Go to PubMed...
    3. deSouza RM, Moro E, Lang AE, Schapira AH. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol 2013; 73(5): 565-575. Go to original source... Go to PubMed...
    4. Gescheidt T, Bareš M. Impulse control disorders in patients with Parkinson´s disease. Acta Neurol Belg 2011; 111(1): 3-9. Go to PubMed...
    5. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23(6): 837-844. Go to original source... Go to PubMed...
    6. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression, and mortality. Neurology 1967; 17: 427-441. Go to original source... Go to PubMed...
    7. Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Znojil V, Rektor I. L-DOPA Induced Dyskinesias and the Continuous Subcutaneous Infusions of Apomorphine - Results of Two Years, Prospective Follow-Up. Mov Disord 2002; 17(1): 188-191. Go to original source... Go to PubMed...
    8. Kianička B, Žák J, Bareš M. Využití perkutánní endoskopické gastrostomie: přehled indikací, popis techniky a současné trendy v neurologii. Ces Slov Neurol Neurochir 2012; 75/108(2): 165-169.
    9. Manca D, Cossu G, Murgia D, Molari A, Ferrigno P, Marcia E, Melis M. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009; 24(15): 2293-2294. Go to original source... Go to PubMed...
    10. Menšíková K, Kaňovský P, Kaiserová M, Nestrašil I, Bareš M. Proměnlivá tvář parkinsonské degenerace. Ces Slov Neurol Neurochir 2013; 76/109(1): 26-34.
    11. Merola A, Zibetti M, Angrisano S, Rizzi L, Lanotte M, Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011; 26(4): 664-670. Go to original source... Go to PubMed...
    12. Nyholm D. Duodopa(R) treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012a; 18(8): 916-929. Go to original source... Go to PubMed...
    13. Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 2001; 104(6): 343-348. Go to original source... Go to PubMed...
    14. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012b; 19(8): 1079-1085. Go to original source... Go to PubMed...
    15. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson´s disease: Treatment guidelines. Neurology 1998; 50(Suppl 3): S15-S50. Go to original source... Go to PubMed...
    16. Palavra NC, Naismith SL, Lewis SJ. Mild cognitive impairment in Parkinson's disease: a review of current concepts. Neurol Res Int 2013; 2013: 576091. Go to original source... Go to PubMed...
    17. Perriol MP, Krystkowiak P, Defebvre L, Blond S, Destée A, Dujardin K. Stimulation of the subthalamic nucleus in Parkinson's disease: cognitive and affective changes are not linked to the motor outcome. Parkinsonism Relat Disord 2006; 12(4): 205-210. Go to original source... Go to PubMed...
    18. Phillips L, Litcofsky KA, Pelster M, Gelfand M, Ullman MT, Charles PD. Subthalamic nucleus deep brain stimulation impacts language in early Parkinson's disease. PLoS One 2012; 7(8): e42829. Go to original source... Go to PubMed...
    19. Rektorova I, Hummelova Z, Balaz M. Dementia after DBS Surgery: A Case Report and Literature Review. Parkinsons Dis 2011: 679283. Go to original source... Go to PubMed...
    20. Rinehardt E, Duff K, Schoenberg M, Mattingly M, Bharucha K, Scott J. Cognitive change on the repeatable battery of neuropsychological status (RBANS) in Parkinson's disease with and without bilateral subthalamic nucleus deep brain stimulation surgery. Clin Neuropsychol 2010; 24(8): 1339-1354. Go to original source... Go to PubMed...
    21. Ruzicka E, Streitova H, Jech R, Kanovsky P, Roth J, Rektorova I, Mecir P, Bares M, Hortova H, Hejdukova B, Rektor I. Amantadine-sulfate infusion in treatment of motor fluctuations ad dyskinesias in Parkinson´s disease. J Neural Transm 2000; 107: 1297-1306. Go to original source... Go to PubMed...
    22. Urban PP, Wellach I, Faiss S, Layer P, Rosenkranz T, Knop K, Weis J. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010; 25(11): 1748-52. Go to original source... Go to PubMed...
    23. Williams AE, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord 2011; 17(5): 321-327. Go to original source... Go to PubMed...
    24. Yágüez L, Costello A, Moriarty J, Hulse N, Selway R, Clough C, Samuel M, Ashkan K. Cognitive predictors of cognitive change following bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease. J Clin Neurosci 2014; 21(3): 445-450. Go to original source... Go to PubMed...
    25. ##
    26. Baláž M. Hluboká mozková stimulace u Parkinsonovy nemoci. Neurol. praxi 2013; 14(5): 229-231.
    27. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J. German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006; 355(9): 896-908. Go to original source... Go to PubMed...
    28. Chrastina J, Pulkrábek J, Rektor I, Novák Z. Stimulace nucleus subthalamicus u Parkinsonovy nemoci. Neurol. praxi, 2004; 2: 71-74.
    29. Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ. CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010: 3; 362(22): 2077-2091. Go to original source...
    30. de Lau LML, Giesbergen PCLM, de Rijk MC Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004; 63: 1240-1244. Go to original source... Go to PubMed...
    31. Litvan I, Aarsland D, Adler CH, et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011; 26: 1814-1824. Go to original source... Go to PubMed...
    32. Lyons KE, Wilkinson SB, Tröster AI, Pahwa R. Long-term efficacy of globus pallidus stimulation for the treatment of Parkinson's disease. Stereotact Funct Neurosurg. 2002; 79(3-4): 214-220. Go to original source... Go to PubMed...
    33. Moro  E, Lozano AM, Pollak P, Agid Y, Rehncrona S, Volkmann J, Kulisevsky J, Obeso JA, Albanese A, Hariz MI, Quinn NP, Speelman JD, Benabid AL, Fraix V, Mendes A, Welter ML, Houeto JL, Cornu P, Dormont D, Tornqvist AL, Ekberg R, Schnitzler A, Timmermann L, Wojtecki L, Gironell A, Rodriguez-Oroz MC, Guridi J, Bentivoglio AR, Contarino MF, Romito L, Scerrati M, Janssens M, Lang AE. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord. 2010; 25(5): 578-586. Go to original source... Go to PubMed...
    34. Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, Contarino MF, Mink MS, Bour LJ, van den Munckhof P, Schmand BA, de Haan RJ, Schuurman PR, de Bie RM. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013; 12(1): 37-44. Go to original source... Go to PubMed...
    35. Petersen  RC. Early diagnosis of Alzheimer's disease: is MCI too late? Curr Alzheimer Res. 2009; 6(4): 324-330. Go to original source... Go to PubMed...
    36. Rouaud T, Dondaine T, Drapier S, Haegelen C, Lallement F, Péron J, Raoul S, Sauleau P, Vérin M. Pallidal stimulation in advanced Parkinson's patients with contraindications for subthalamic stimulation. Mov Disord. 2010; 25(12): 1839-1846. Go to original source... Go to PubMed...
    37. Schüpbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Malt?te D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group.Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013; 368(7): 610-622. Go to original source... Go to PubMed...
    38. Videnovic A, Metman LV. Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting. Mov Disord. 2008; 23(3): 343-349. Go to original source... Go to PubMed...
    39. Weaver F, Follet K, Hur K, Ippolito D, Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg. 2005; 103(6): 956-967. Go to original source... Go to PubMed...
    40. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD. CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009; 301(1): 63-73. Go to PubMed...
    41. Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012 3; 79(1): 55-65. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.